A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Effect of MK-1167 on QTc in Healthy Adult Participants
概览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Number of Participants Who Experience an Adverse Event (AE)
概览
简要总结
The goal of this trial is to learn about the safety of MK-1167 and if people tolerate it.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •but are not limited to the following:
- •Is in good health
- •Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive
- •The key inclusion criteria but are not limited to the following:
- •Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
- •Is a smoker and/or has used nicotine or nicotine-containing products (for example, nicotine patch and electronic cigarette) within the past 3 months
排除标准
- 未提供
研究组 & 干预措施
MK-1167
MK-1167 administered orally
干预措施: MK-1167 (Drug)
Placebo
Placebo for MK-1167 administered orally
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants Who Experience an Adverse Event (AE)
时间窗: Up to approximately 9 weeks
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
Number of Participants Who Discontinue Study Treatment Due to an AE
时间窗: Up to approximately 1 week
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
次要结局
未报告次要终点